openPR Logo
Press release

Learn Details of the Central Nervous System Disorder Drugs Market Report

Learn Details of the Central Nervous System Disorder Drugs

The market for central nervous system disorder drugs comprise of drugs used for the treatment of diseases affecting the brain or spinal cord such as epilepsy, Parkinson’s disease, Alzheimer’s disease, depression, anxiety and bipolar disorders. Epilepsy is a chronic brain disorder characterized by recurring seizures. Parkinson’s disease is a degenerative CNS disorder associated with symptoms including tremor, rigidity, akinesia and bradykinesia. It is reported by Parkinson’s disease Foundation that as of now 7-10 million people are affected with Parkinson’s disease across the globe. These diseases are generally caused by neurodegeneration, autoimmune disorders, trauma, tumors and vascular disorders.

View TOC for this Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=1475

The market for CNS disorders is categorized into three segments namely psychiatry, neurology and pain drugs market. Psychiatry drugs market is further segmented into anxiety, depression, bipolar disorders, schizophrenia and ADHD (attention deficit hyperactivity disorder). Neurology drugs market is divided into migraine, epilepsy, Parkinson’s disease, multiple sclerosis, narcolepsy and and Alzheimer’s disease. Pain management drugs market segment comprises of drugs used to treat pain associated with CNS disorders. Among these psychiatry segment holds the largest share accounting for more than 40% followed by neurology and pain segment.

Rapidly increasing geriatric population base resulting in an elevated incidence levels of CNS disorders such as Alzheimer’s disease, Parkinson’s disease, schizophrenia and multiple disorders is one of the key factors driving the growth of the market for CNS disorders.. Currently, there is no drug to cure Alzheimer’s disease, the available medicines only treat the severity of symptoms and improve the quality of life to some extent. That is why companies such as Eli Lilly, Baxter International and Novartis AG are investing heavily in research and development in order to accelerate the treatment of Alzheimer’s disease.

Geographically, North America holds the largest share of the total market of CNS disorders followed by Europe and Asia-Pacific. Asia-Pacific is projected to grow at a CAGR more than other regions on account of high prevalence of diseases such as epilepsy, Parkinson’s disease and Alzheimer’s disease. As of 2012, WHO (world health organization) suggests that around 50 million people are suffering from epilepsy worldwide, most of them (approximately 80%) belong to developing nations.

Fill the form to gain deeper insights on this market @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1475

Some of the key players operating in the market for CNS disorders are Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis AG, Sanofi, Merck & Co., Abbott Laboratories, Eli Lilly, UCB, Bristol-Meyers Squibb Co. and Astellas Pharma, Inc.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Learn Details of the Central Nervous System Disorder Drugs Market Report here

News-ID: 785759 • Views: 149

More Releases from Transparency Market Research

Global Waste to Energy Market is Presumed to be Valued at US$ 32 Bn by 2026
Overview TMR’s report on the Waste-to-energy Technologies Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Waste-to-energy Technologies Market serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Waste-to-energy Technologies Market over the forecast period.
FPSO Market is Likely to Reach a Value of US$ 66 Bn by 2026
Overview TMR’s report on the FPSO Vessels and Equipments Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the FPSO Vessels and Equipments Market serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the FPSO Vessels and
Recycled Plastic & Plastic Waste to Oil Market Demand and Growth Analysis with F …
Overview TMR’s report on the Recycled Plastics & Plastic Waste to Oil Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Recycled Plastics & Plastic Waste to Oil Market serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely
Chlorinated Paraffins Market – Size will Observe Lucrative Surge by the End202 …
Overview TMR’s report on the Chlorinated Paraffin Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Chlorinated Paraffin Market serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Chlorinated Paraffin Market over the forecast period.

All 5 Releases


More Releases for Parkinson’s

Parkinson’s Disease Therapeutic Market- Trends, Outlook 2025
Parkinson’s disease (PD) is a chronic disorder characterized by the malfunctioning and death of vital nerve cells in the brain, and can be characterized by tremor, dementia, and depression. Parkinson’s disease progression leads to uncontrolled body movement of the patient. There is no cure presently for parkinson’s disease only treatments options such as medication and surgery to manage the symptoms are available. Parkinson’s disease mainly affects people over 50 and
Parkinson’s disease Therapeutics Parkinson’s disease Therapeutics Market to …
This report studies the global Parkinson's Disease Therapeutics market, analyzes and researches the Parkinson's Disease Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like GSK Novartis Boehringer Ingelheim Teva Pharmaceutical Abbvie ….. Ask for sample copy @ https://www.researchtrades.com/request-sample/1199125 Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia Market segment by Type, Parkinson's Disease Therapeutics can be split into Medications Therapeutics Medical Devices Therapeutics Buy
US Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in the United States in recent years and it most likely to continue rising in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. The society pays a significant amount towards treating this disease in the country. It is estimated that the total cost to the nation exceeds
Europe Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been estimated that currently, more than 1 million in Europe are affected by Parkinson’s disease. This figure is most likely to double by 2030. Among the most common neurodegenerative disease (after Alzheimer’s disease), Parkinson’s is the second most common and it is expected that
Parkinson’s Disease - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Parkinson’s Disease - Heat Map and Analysis to its growing collection of premium market research reports. Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the progressive loss of muscular control, leading to resting tremor, rigidity, akinesia and postural reflex impairment. PD is an age-related disorder; symptoms typically begin to first appear in patients in their mid-sixties,
New Education Options for Parkinson’s Caregivers
(4/30/2012- Gilbert, Ariz.) When a loved one is diagnosed with Parkinson’s Disease (PD), it becomes clear that Parkinson’s is a life- changing experience for the entire family — particularly for the primary care provider, who is most often a spouse, child or parent. Family caregivers may not think of themselves as a care providers or recognize their new caregiving tasks. As family members begin helping with doctor visits, taking over financial